Premium
Near‐Infrared Responsive PEGylated Gold Nanorod and Doxorubicin Loaded Dissolvable Hyaluronic Acid Microneedles for Human Epidermoid Cancer Therapy (Adv. Therap. 2/2018)
Author(s) -
Hao Ying,
Chen YuWen,
Lei MinYi,
Zhang TaoYe,
Cao YiPing,
Peng JinRong,
Chen LiJuan,
Qian ZhiYong
Publication year - 2018
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.201870004
Subject(s) - hyaluronic acid , doxorubicin , peg ratio , in vivo , epidermoid carcinoma , medicine , materials science , penetration (warfare) , nanorod , cancer , biomedical engineering , pharmacology , cancer research , chemotherapy , nanotechnology , surgery , biology , anatomy , microbiology and biotechnology , finance , operations research , engineering , economics
Human Epidermoid Cancer In article no. 1800008 , ZhiYong Qian and co‐workers develop a near‐infrared (NIR) responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acid (HA) microneedle (GNR‐PEG&DOX@HA MN) for human epidermoid cancer therapy. The GNR‐PEG&DOX@HA MNs have good skin penetration capability and the release behavior of the DOX from GNR‐PEG&DOX@HA MNs can be controlled by near infra‐red light. An in vivo antitumor study, shows that transcutaneously delivered GNR‐PEG&DOX@HA MNs demonstrates remarkable antitumor efficacy, such that all treated mice were cured without recurrence after only one treatment.